FYCOMPA FILM-COATED TABLET 2 MG

TABLET, FILM COATED

**4.2 Posology and method of administration** Posology FYCOMPA must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability. Perampanel should be taken orally once daily at bedtime. The physician should prescribe the most appropriate formulation and strength according to weight and dose. Alternate formulations of perampanel are available, including oral suspension. _Partial Onset Seizures_ \[Monotherapy\] The following table summarises the recommended posology for adults, adolescents, and children from 4 years of age. More details are provided below the table.  _Adults, adolescents age ≥12 years_ The starting oral dose is 2 mg once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 2 weeks or longer. The maintenance dose is 4–8 mg once daily. Dosage may be increased or decreased as necessary by 2 mg or less at intervals of 2 weeks or longer based on individual clinical response and tolerability, but the maximum daily dose should not be over 8 mg. _Children (from 4 to 11 years) weighing ≥30 kg_ The starting oral dose is 2 mg once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 2 weeks or longer. The maintenance dose is 4–8 mg once daily. Dosage may be increased or decreased as necessary by 2 mg or less at intervals of 2 weeks or longer based on individual clinical response and tolerability, but the maximum daily dose should not be over 8 mg. _Children (from 4 to 11 years of age) weighing 20 kg and <30 kg_ The starting oral dose is 1 mg once daily as perampanel at bedtime, and the daily dose may then be increased by 1 mg at intervals of 2 weeks or longer. The maintenance dose is 4–6 mg once daily. Dosage may be increased or decreased as necessary by 1 mg or less at intervals of 2 weeks or longer based on individual clinical response and tolerability, but the maximum daily dose should not be over 6 mg. _Children (from 4 to 11 years of age) weighing <20 kg_ The starting oral dose is 1 mg once daily as perampanel at bedtime, and the daily dose may then be increased by 1 mg at intervals of 2 weeks or longer. The maintenance dose is 2–4 mg once daily. Dosage may be increased or decreased as necessary by 1 mg or less at intervals of 2 weeks or longer based on individual clinical response and tolerability, but the maximum daily dose should not be over 4 mg. \[Adjunctive therapy\] Perampanel at doses of 4 mg/day to 12 mg/day has been shown to be effective therapy in partial-onset seizures. The following table summarises the recommended posology for adults, adolescents and children from 4 years of age. More details are provided below the table.  _Adults, adolescents age ≥ 12 years_ Treatment with FYCOMPA should be initiated with a dose of 2 mg/day. The dose may be increased based on clinical response and tolerability by increments of 2 mg (either weekly or every 2 weeks as per half life considerations described below) to a maintenance dose of 4 mg/day to 8 mg/day. Depending upon individual clinical response and tolerability at a dose of 8 mg/day, the dose may be increased by increments of 2 mg/day to 12 mg/day. Patients who are taking concomitant medicinal products that do not shorten the half life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2 week intervals. Patients who are taking concomitant medicinal products that shorten the half life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1 week intervals. _Children (from 4 to 11 years) weighing ≥ 30 kg_ Treatment with Fycompa should be initiated with a dose of 2 mg/day. The dose may be increased based on clinical response and tolerability by increments of 2 mg (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 4 mg/day to 8 mg/day. Depending upon individual clinical response and tolerability at a dose of 8 mg/day, the dose may be increased by increments of 2 mg/day to 12 mg/day. Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1-week intervals. _Children (from 4 to 11 years of age) weighing 20 kg and < 30 kg_ Treatment with Fycompa should be initiated with a dose of 1 mg/day. The dose may be increased based on clinical response and tolerability by increments of 1 mg (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 4 mg/day to 6 mg/day. Depending upon individual clinical response and tolerability at a dose of 6 mg/day, the dose may be increased by increments of 1 mg/day to 8 mg/day. Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1-week intervals. _Children (from 4 to 11 years of age) weighing < 20 kg_ Treatment with Fycompa should be initiated with a dose of 1 mg/day. The dose may be increased based on clinical response and tolerability by increments of 1 mg (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 2 mg/day to 4 mg/day. Depending upon individual clinical response and tolerability at a dose of 4 mg/day, the dose may be increased by increments of 0.5 mg/day to 6 mg/day. Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1-week intervals. _Primary Generalised Tonic-Clonic Seizures_ Perampanel at a dose up to 8 mg/day has been shown to be effective in primary generalized tonic clonic seizures. The following table summarises the recommended posology for adults, adolescents and children from 7 years of age. More details are provided below the table.  _Adults, adolescents age ≥ 12 years_ Treatment with FYCOMPA should be initiated at a dose of 2 mg/day. The dose may be increased based on clinical response and tolerability by increments of 2 mg (either weekly or every 2 weeks, as per half-life considerations described below) to a maintenance dose of up to 8 mg/day. Depending upon individual clinical response and tolerability at a dose of 8 mg/day, the dose may be increased up to 12 mg/day, which may be effective in some patients (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see Section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1-week intervals. _Children (from 7 to 11 years) weighing ≥ 30 kg_ Treatment with Fycompa should be initiated with a dose of 2 mg/day. The dose may be increased based on clinical response and tolerability by increments of 2 mg (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 4 mg/day to 8 mg/day. Depending upon individual clinical response and tolerability at a dose of 8 mg/day, the dose may be increased by increments of 2 mg/day to 12 mg/day. Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1-week intervals. _Children (from 7 to 11 years of age) weighing 20 kg and < 30 kg_ Treatment with Fycompa should be initiated with a dose of 1 mg/day. The dose may be increased based on clinical response and tolerability by increments of 1 mg (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 4 mg/day to 6 mg/day. Depending upon individual clinical response and tolerability at a dose of 6 mg/day, the dose may be increased by increments of 1 mg/day to 8 mg/day. Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1-week intervals. _Children (from 7 to 11 years of age) weighing < 20 kg_ Treatment with Fycompa should be initiated with a dose of 1 mg/day. The dose may be increased based on clinical response and tolerability by increments of 1 mg (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 2 mg/day to 4 mg/day. Depending upon individual clinical response and tolerability at a dose of 4 mg/day, the dose may be increased by increments of 0.5 mg/day to 6 mg/day. Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) should be titrated no more frequently than at 1-week intervals. _Paediatrics population_ The safety and efficacy of FYCOMPA have not yet been established in children below 4 years of age in the POS indication or in children below 7 years of age in the PGTCS indication. _Elderly Patients (65 years of age and above)_ Clinical studies of FYCOMPA in epilepsy did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Analysis of safety information in 905 perampanel-treated elderly patients (in double blind studies conducted in non-epilepsy indications) revealed no age-related differences in the safety profile. In combination with the lack of age-related difference in perampanel exposure, the results indicate that dose adjustment in the elderly is not required. Perampanel should be used with caution in elderly taking into account the drug interaction potential in polymedicated patients (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Renal Impairment_ Dose adjustment is not required in patients with mild renal impairment. Use in patients with moderate or severe renal impairment or patients undergoing hemodialysis is not recommended. _Hepatic Impairment_ Dose increases in patients with mild and moderate hepatic impairment should be based on clinical response and tolerability. For patients with mild or moderate hepatic impairment, dosing can be initiated at 2 mg. Patients should be up-titrated using 2 mg doses no faster than every 2 weeks based on tolerability and effectiveness. Perampanel dosing for patients with mild and moderate impairment should not exceed 8 mg. Use in patients with severe hepatic impairment is not recommended. _Missed Dose_ Single missed dose: As FYCOMPA has a long half-life, the patient should wait and take their next dose as scheduled. If more than 1 dose has been missed, for a continuous period of less than 5 half-lives (3 weeks for patients not taking FYCOMPA metabolism-inducing anti-epileptic drugs (AED), 1 week for patients taking FYCOMPA metabolism-inducing AEDs (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_), consideration should be given to re-start treatment from the last dose level. If a patient has discontinued FYCOMPA for a continuous period of more than 5 half-lives, it is recommended that initial dosing recommendations given above should be followed. _Withdrawal_ When withdrawing, the dose should be gradually reduced to minimize the potential for rebound seizures. However, due to its long-half life and subsequent slow decline in plasma concentrations, FYCOMPA can be discontinued abruptly if absolutely needed. Method of administration Fycompa should be taken as single oral dose at bedtime. It may be taken with or without food (see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). The tablet should be swallowed whole with a glass of water. It should not be chewed, crushed or split. The tablets cannot be split accurately as there is no break line.